Treatment decisions based on individual estimated lifetime benefit versus individual estimated 10-year absolute risk reduction: a cost-effectiveness analyses with PCSK9 inhibition.
25 August 2018 (00:00 - 00:00)
Organised by:
About the speaker
University Medical Center Utrecht, Utrecht (Netherlands (The))
4 More presentations in this session
Doctor N. Sasaki (Hiroshima, JP)
Professor P. Schwandt (Munich, DE)
Access the full session
The Event
ESC Congress 2018
25 August - 29 August 2018
You may be interested in
Congress Presentation
Congress Presentation
Congress Presentation
